


Bafrekalant

Cat. No.:	HY-145554		
CAS No.:	2256770-44-0		
Molecular Formula:	C ₂₉ H ₃₁ ClN ₆ O ₂		
Molecular Weight:	531.05		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (470.77 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.8831 mL	9.4153 mL	18.8306 mL
5 mM	0.3766 mL	1.8831 mL	3.7661 mL
10 mM	0.1883 mL	0.9415 mL	1.8831 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.92 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Bafrekalant is a diazabicyclic substituted imidazo[1,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA